Navigation Links
CoLucid Pharmaceuticals Raises $7.5 Million of Planned $9.5 Million
Date:8/30/2011

DURHAM, N.C., Aug. 30, 2011 /PRNewswire-iReach/ -- CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced today that it has raised $7.5 million of a planned $9.5 million convertible note financing from its existing investors to support further late stage development of lasmiditan.  Participating in the financing were Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures.

"This financing provides important working capital for CoLucid to further advance lasmiditan into Phase 3 development," remarked Thomas P. Mathers, Chief Executive Officer of CoLucid.  "We are embarking on additional clinical studies to further differentiate lasmiditan's safety profile from the triptan class of anti-migraine agents, as well as discussing with the FDA our final Phase 3 plans." said Mr. Mathers.

The Company is speaking with potential partners and is interacting with the FDA, and plans to advance lasmiditan into pivotal studies in 2012.

About Lasmiditan

Lasmiditan is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies.  Lasmiditan is a member of a novel chemical class called "ditans" and, unlike triptans, penetrates the central nervous system (CNS) and selectively targets 5-HT1F receptors expressed in the trigeminal pathway.  Lasmiditan does not interact with vasoconstrictor 5-HT1B/1D receptors activated by triptans.

Five clinical studies have been successfully completed outside of the U.S., including a Phase 2b double blind placebo controlled oral dose ranging study treating a single migraine attack which was completed in 2010. In the Phase 2b study, lasmiditan achieved its primary endpoint of reducing a moderate or severe headache at baseline to mild or none 2 hours after dosing (p<0.0001) in 391 patients. Differentiation of individual doses from placebo was seen as early as 30 minutes after dosing. Lasmiditan also achieved secondary endpoints, including relief of nausea, photophobia and phonophobia.  Importantly, because there was no evidence of drug-related cardiovascular effects or chest symptoms in the previous five clinical studies, CoLucid expects the pivotal Phase 3 studies to confirm that lasmiditan's side effect profile is highly differentiated from triptans and ergotamines.

About CoLucid Pharmaceuticals, Inc.

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures. The company's pipeline includes lasmiditan, a novel treatment for migraine headache, COL-204 for wake promotion, and a conjugated stigmine platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. For more information, please visit CoLucid at www.colucid.com.

Media Contact: Kathy Kelly, CoLucid Pharmaceuticals, Inc., 919-806-4304, kkelly@colucid.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE CoLucid Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CoLucid Appoints Thomas P. Mathers as Chief Executive Officer
2. CoLucid Pharmaceuticals Receives Clearance for Investigational New Drug (IND) Application for Lasmiditan for the Treatment of Acute Migraine
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... -- Varian Medical Systems (NYSE: VAR ) announced ... of fiscal year 2017 following the close of regular trading ... followed by a teleconference available to all interested parties at ... the conference call webcast will be available on the company ... and replay: ...
(Date:3/29/2017)...  NuVasive, Inc. (NASDAQ: NUVA), a leading medical ... minimally disruptive, procedurally-integrated solutions, today announced U.S. Food ... CoRoent® Small Interbody™ System indicated for intervertebral body ... spine. This marks the first U.S. clearance for ... to four contiguous levels. Cervical radiculopathy ...
(Date:3/29/2017)... 2017 NetworkNewsWire Editorial Coverage  ... There are a ... regulating marijuana, but economic arguments also favor its legalization. The ... enforcement costs. However, to legalize and regulate marijuana requires an ... (OTC: SING) ( SING Profile ), American Cannabis Company (OTC: ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , ... announce the finalization of the company’s executive management team with prominent executives from both ... is Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more than ...
(Date:3/29/2017)... ... 29, 2017 , ... The assembly of synthetic DNA has ... repetitive steps and often scientists require many different versions of DNA. Therefore, this ... in a lower error rate and cost saving for reagents and consumables. , ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... of Pittsburgh now have easier access to the robotic-assisted total-hip and partial-knee ... Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital recently started ...
(Date:3/29/2017)... ... March 29, 2017 , ... AvePoint , the Microsoft ... office location in Richmond, Virginia, located at the Riverfront Plaza, 901 East Byrd Street. ... Governor of Virginia Ralph S. Northam and Mayor of Richmond Levar M. Stoney. , ...
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, ... public to take the Diabetes Risk Test to find out if they are at ... World Airports will light up the evening sky by programming the LAX pylons the ...
Breaking Medicine News(10 mins):